Pharmaceutical CDMO Market Size & Share 2026-2035
Market Size - By Service (Contract Development, Contract Manufacturing, Packaging & Labelling, Regulatory Support & Quality Services, Other Services), By Product (API, Finished Drug Formulations (FDF)), By Molecule Type (Small Molecule, Large Molecule), By Therapeutic Area (Oncology, Metabolic & Endocrine, Cardiovascular, CNS & Psychiatry, Infectious Diseases & Vaccines, Other Therapeutic Areas), and By End Use (Pharmaceutical Companies, Biotechnology Companies, Other End Users), Growth Forecast. The market forecasts are provided in terms of revenue (USD Million).
Report ID: GMI16057
|
Published Date: June 2026
|
Report Format: PDF
Download Free PDF
Authors:
Monali Tayade, Shishanka Wangnoo
Pharmaceutical CDMO Market Size
The global pharmaceutical CDMO market reached USD 173.7 billion in 2025. The market is projected to advance from USD 184.9 billion in 2026 to USD 342 billion by 2035, compounding at a CAGR of 7.1% over the forecast period, according to the latest report published by Global Market Insights Inc.
Pharmaceutical CDMO Market Key Takeaways
Market Size & Growth
Regional Dominance
Key Market Drivers
Challenges
Opportunity
Key Players
Structural forces including accelerating outsourcing adoption by both large pharmaceutical companies and early-stage biotechs, a deepening biologics pipeline, and persistent capacity constraints in sterile fill-finish and advanced therapy manufacturing are reinforcing demand across the value chain. At the same time, regulatory tightening and intensifying competition in commodity segments are introducing pressure on margins and operational complexity for mid-tier operators.
Key Drivers
Drivers Impact Analysis
Driver
Impact on CAGR Forecast
Geographic Relevance
Impact Timeline
Increasing outsourcing by pharma and biotech companies
+2.3–3.2%
Global
Short term (≤ 2 years)
Growing biologics and advanced therapy pipeline
+1.8–2.6%
North America, Europe, Asia Pacific
Medium term (2–4 years)
Capacity constraints and specialized infrastructure needs
+1.5–2.2%
North America, Europe
Short term (≤ 2 years)
Rising R&D investments and drug approvals globally
+1.3–2%
Global
Medium term (2–4 years)
Increasing Outsourcing by Pharmaceutical and Biotech Companies
Rising operational costs and a sharpened focus on core competencies primarily drug discovery, clinical development, and commercial access are driving both large pharma and early-stage biotech companies to outsource an increasing share of their manufacturing value chain. Industry analysis of FDA drug approval data indicates that 73% of novel drug approvals in 2025 involved outsourced API manufacturing, above the 11-year average of 61% and consistent with the record 74% rate recorded in 2024. Finished-dose outsourcing reached 65% in 2025 the highest level on record and materially above the long-run average of 50% confirming the structural shift toward contract-based production models.[1]Pharma Manufacturing, pharmamanufacturing.com Smaller and mid-sized innovators, which account for the majority of the current global pipeline, continue to rely on CDMOs more heavily than their large-cap peers, sustaining baseline demand independent of macroeconomic cycles.
Growing Biologics and Advanced Therapy Pipeline
The global drug development pipeline reached 22,825 molecules in 2024, a 7.2% expansion over the prior year, with biologics, monoclonal antibodies, and advanced therapy medicinal products representing an increasing proportion of late-stage candidates. Biologics accounted for 45% of FDA novel drug approvals in 2025, while the European Medicines Agency recommended 104 medicines for authorization in Europe including a record 41 biosimilars reflecting the depth of the approved biologics portfolio now requiring commercial manufacturing.[2]European Medicines Agency (EMA), ema.europa.eu The manufacturing complexity associated with these modalities from process development to cold-chain handling systematically increases reliance on specialized CDMOs, particularly for small and mid-sized innovators without in-house biologics manufacturing infrastructure.
Capacity Constraints and Need for Specialized Infrastructure
Available sterile fill-finish capacity, viral vector manufacturing suites, and high-potency API (HPAPI) production infrastructure remain constrained relative to pipeline demand. This imbalance has extended lead times and elevated outsourcing urgency, particularly for cell and gene therapy developers. Industry data shows that 82.6% of cell and gene therapy facilities are now outsourcing at least some manufacturing activity, with mammalian and microbial fermentation platforms each recording outsourcing rates above 77% levels not seen in previous decades.[3]BioPlan Associates, bioplanassociates.com The gap between available specialist capacity and pipeline volume is expected to persist through the medium term, sustaining outsourcing demand in the most technically complex service categories.
Rising R&D Investments and Drug Approvals Globally
Global R&D expenditure by large pharmaceutical companies reached USD 190 billion in 2024, representing a 73% increase over five years and exceeding 25% of industry sales for the first time. PhRMA member companies alone invested USD 104.3 billion in R&D in 2024, up from USD 96 billion in 2023. This sustained investment is generating a larger and more complex drug portfolio across clinical stages, directly increasing CDMO demand at every point from development through commercialization. Biopharma funding reached a 10-year high of USD 102 billion in 2024, sustaining early-stage biotech activity and reinforcing outsourcing pipeline volumes.
Key Challenges
Restraints Impact Analysis
Challenge
Impact on CAGR Forecast
Geographic Relevance
Impact Timeline
Regulatory complexity and compliance burden
−0.9–1.4%
Global
Short term (≤ 2 years)
Pricing pressure and competition
−0.8–1.2%
Global
Short term (≤ 2 years)
Regulatory Complexity and Compliance Burden
CDMOs operating across multiple geographies must simultaneously satisfy FDA current Good Manufacturing Practice (cGMP) regulations, EMA guidelines, ICH technical standards, and jurisdiction-specific requirements. Inspection frequency and regulatory scrutiny have intensified in the post-pandemic period, with agencies placing greater emphasis on data integrity, supply chain transparency, and site-level quality systems. For CDMOs managing multiple client programs across shared facilities, the cost and management overhead of continuous GMP compliance is a meaningful structural constraint, particularly for mid-tier operators. Mitigation strategies include investment in enterprise quality management systems, dedicated site-level regulatory affairs functions, and strategic facility segregation for high-risk modalities.
Pricing Pressure and Competition
Contract manufacturing of small molecule APIs and solid-dose finished formulations remains highly competitive, with pricing pressure intensifying as capacity from Asian manufacturers particularly in China and India competes aggressively on cost. Margin compression in commodity service categories is pushing CDMOs to differentiate through service breadth, technology investment, and regulatory track record. The more consequential shift is the growing bifurcation between commodity CDMO services, where pricing competition is acute, and specialized services such as biologics drug product manufacturing, HPAPI synthesis, and cell and gene therapy production where technical barriers remain high and pricing holds firmer.
Pharmaceutical CDMO Market Trends
Structural Shift Toward Biologics and Complex Modalities
The composition of the global pharmaceutical pipeline has fundamentally changed over the past decade, with biologics, cell and gene therapies, and ADCs now representing a majority of new development starts at large and mid-sized pharma companies. Biologics accounted for 45% of FDA novel drug approvals in 2025, with the manufacturing demands of this product mix including mammalian cell culture optimization, viral clearance validation, and sterile fill-finish qualitatively different from small-molecule API synthesis. These demands require infrastructure and process expertise that most drug developers do not maintain at commercial scale in-house, making CDMO partnerships structurally necessary rather than discretionary.
The real-world impact of this trend is most visible at the capital investment level. Fujifilm Diosynth Biotechnologies launched the first phase of a major expansion at its Hillerød, Denmark facility in November 2024, adding six mammalian cell bioreactors and bringing the total site capacity to 12 × 20,000-liter bioreactors, with fill-finish production scheduled to commence by mid-2025 and a full 51,500 m² footprint planned for 2026. Advanced therapies represented the fastest-growing biologics CDMO revenue segment in 2024, expanding 37% year-over-year as clinical-to-commercial transitions accelerated in cell and gene therapy. The underlying driver is a structural change in drug development strategy: a growing cohort of drug developers is designing molecules that require CDMO partnership from inception, rather than at the point of scale-up.
In our H1 2025 research covering 62 biopharma procurement leads across North America and Europe, 74% indicated that biologics manufacturing capability specifically mammalian cell culture and fill-finish was the primary criterion in CDMO partner selection, ahead of cost and geographic proximity. This compares to only 41% citing technical capability as the primary factor in a comparable 2022 survey, reflecting how decisively the selection calculus has shifted over three years. The data indicates that CDMOs with validated biologics capacity and strong regulatory track records are accruing disproportionate demand relative to their total capacity footprint.
Preference for Integrated End-to-End CDMO Partnerships
Drug sponsors are rationalizing their CDMO vendor base, moving from multi-supplier models toward integrated partnerships where a single CDMO covers development, scale-up, clinical manufacturing, commercial production, packaging, and regulatory support. This preference reduces technical transfer risk, compresses program timelines, and simplifies commercial supply governance all high-priority concerns for mid-sized biotechs managing multiple pipeline assets with limited internal resources. Outsourcing has now reached record levels across all bioprocessing platforms, with 77.5% of mammalian and 78% of microbial fermentation facilities engaged in some form of outsourcing activity, up substantially from rates recorded a decade ago.
CDMOs that have invested in full-service platforms spanning integrated chemistry, manufacturing, and controls (CMC) development, clinical supply, and commercial manufacturing are gaining disproportionate share in large pharma vendor consolidation programs. PCI Pharma Services exemplifies this investment direction, committing over USD 365 million across US and EU facilities in 2024 to expand advanced drug delivery capabilities, drug-device combination assembly, and advanced packaging positioning the company as a single-source partner for clinical through commercial supply.
Reshoring and Geopolitical Supply Chain Restructuring
Geopolitical developments including US BIOSECURE Act provisions restricting certain Chinese CDMOs from US-funded programs, tariff policy shifts, and heightened supply chain security concerns have triggered a significant reallocation of CDMO capital investment. The pharmaceutical contract manufacturing landscape underwent a material readjustment in 2025, with the US capturing USD 18.48 billion in disclosed CDMO investments and India recording USD 3.31 billion in second place. US CDMOs reported a 20% increase in requests for proposals for domestic manufacturing since early 2024, while Indian CDMOs noted a 15% rise in contracts for US markets over the same period. The second-order effect is a medium-term structural shift in commercial manufacturing siting one that is reshaping competitive positioning across both global and regional CDMOs and creating capacity-building opportunities in India, Ireland, and Southeast Asia as Western sponsors seek geopolitically diversified supply chains.
Pharmaceutical CDMO Market Analysis
By Service
Contract Manufacturing Services
Contract manufacturing services represent the dominant revenue category at 48.7% of the global pharmaceutical CDMO market in 2025, encompassing commercial-scale API and drug product manufacturing executed under multi-year supply agreements between CDMOs and their pharmaceutical and biotech clients. This segment's scale reflects the market's structural maturation: the majority of commercial drug supply for both originator and generic portfolios is now fulfilled through contracted manufacturing relationships rather than captive in-house facilities. Industry analysis of FDA drug approval data indicates that 73% of novel drug approvals in 2025 involved outsourced API manufacturing and 65% involved outsourced finished-dose manufacturing both at or near record levels confirming that commercial manufacturing outsourcing has become the default model across molecule classes. Demand is further supported by the growing volume of biologics commercial launches, which require large-scale mammalian cell culture, sterile fill-finish, and cold-chain supply capabilities typically provided by dedicated CDMO sites.
Lonza, Thermo Fisher Scientific (Patheon), and Samsung Biologics collectively account for a significant share of commercial manufacturing agreements in the biologics drug product sub-category, reflecting the capital intensity and regulatory depth required to compete effectively at commercial scale.
Contract Development Services
Contract development services account for 23.1% of global pharmaceutical CDMO revenues in 2025, spanning formulation development, process development, analytical method development, and clinical manufacturing from Phase I through Phase III. This segment is positioned at the earliest stage of the CDMO value chain and serves as the entry point through which CDMOs establish client relationships that frequently evolve into long-term commercial manufacturing agreements. Demand is driven by the depth of the global drug pipeline more than 22,800 molecules were in clinical development as of 2024 combined with the technical complexity of modern drug candidates, particularly biologics and advanced therapies, that require specialized process expertise to advance through development stages.
Biopharma funding reached a 10-year high of USD 102 billion in 2024, sustaining early-stage biotech activity and reinforcing demand for development-stage outsourcing. CDMOs with integrated development platforms connecting formulation science, process development, analytical services, and GMP clinical manufacturing under a single program structure are increasingly preferred by sponsors seeking to reduce technical transfer risk and consolidate CMC program management with a single partner.
Packaging and Labelling
Packaging and labelling services account for 12.4% of global pharmaceutical CDMO revenues in 2025, encompassing primary and secondary packaging, serialization and track-and-trace compliance, clinical trial packaging, and specialized formats including blister packaging, vials, prefilled syringes, and drug-device combination assembly. The segment has gained strategic importance as pharmaceutical supply chains navigate increasingly complex regulatory serialization requirements across the US (Drug Supply Chain Security Act), EU (Falsified Medicines Directive), and Asian markets, requiring CDMOs to maintain compliant packaging infrastructure and validated digital track-and-trace systems across geographies.
Advanced packaging capabilities including isolator-protected vial filling, lyophilization, and autoinjector assembly are particularly in demand as biologic drug product programs move from clinical to commercial stages. PCI Pharma Services committed over USD 365 million to packaging capacity expansion across its US and EU facilities in 2024, including a 545,000-square-foot facility in Rockford, Illinois dedicated to advanced drug delivery and drug-device combination assembly, with the first phase operational from Q3 2025. The segment's growth is also supported by the expansion of patient-centric device formats including autoinjectors, wearable injectors, and combination products which require specialized assembly capabilities well beyond standard secondary packaging.
Regulatory Support & Quality Services
Regulatory support and quality services account for 9.8% of global pharmaceutical CDMO market revenues in 2025, providing pharmaceutical and biotech clients with expertise in regulatory submissions, CMC documentation, GMP compliance management, quality systems maintenance, and interaction with agencies including the FDA, EMA, and national competent authorities. The segment's relevance has grown alongside the increasing complexity of global regulatory frameworks: CDMOs now frequently serve as the primary regulatory interface for clients lacking in-house regulatory infrastructure, particularly small biotechs and virtual pharma companies advancing molecules toward a first commercial approval.
The EMA's record recommendation of 41 biosimilars in 2025 and the FDA's 46 novel drug approvals in the same year[4]U.S. Food and Drug Administration (FDA), fda.gov have generated substantial post-approval regulatory work including post-marketing change management, manufacturing site variations, and annual product reviews that sustains demand for specialized regulatory services well beyond initial authorization. CDMOs with established regulatory relationships across multiple agencies provide sponsors with a meaningful competitive advantage in market access timelines, making regulatory capability an increasingly influential differentiator in CDMO partner selection alongside technical manufacturing performance.
Other Services
Other CDMO services represent 6% of global revenues in 2025 and encompass technology transfer, supply chain and logistics management, process optimization, and clinical trial support activities. Technology transfer the systematic replication of a manufacturing process from a developer's site or a prior CDMO to a new commercial manufacturing facility is among the most complex and risk-intensive activities in the pharmaceutical supply chain, and CDMOs with experienced technical transfer teams and platform-aligned manufacturing systems command a meaningful capability premium in contract negotiations.
Supply chain and logistics services are growing in strategic importance as pharmaceutical companies seek end-to-end supply chain visibility from active ingredient sourcing through final market distribution, particularly as geopolitical developments increase the cost of unmanaged supply chain disruption. Process optimization services including continuous manufacturing implementation, process analytical technology (PAT) adoption, and yield improvement programs generate incremental revenue as CDMOs apply engineering expertise to reduce per-unit manufacturing costs for commercial-stage clients. The underlying driver of growth in this category is the deepening complexity of sponsor-CDMO relationships, which increasingly extend beyond discrete service transactions into comprehensive program management partnerships spanning the full operational supply chain.
By Product
Active Pharmaceutical Ingredient (API)
The API segment accounted for 40.9% of the global pharmaceutical CDMO market in 2025, representing a substantial revenue pool anchored by sustained demand across chemical synthesis, biologics drug substance manufacturing, and high-potency compound production. At the sub-segment level, chemical APIs hold the largest share at 51.7% of API revenues, driven by the continued commercial volume of small-molecule drugs under long-term supply agreements. Biological APIs including monoclonal antibodies, recombinant proteins, fusion proteins, and oligonucleotides represent 31.6% of segment revenues, growing as biologic drug approvals accumulate globally and biosimilar market entries generate incremental manufacturing demand.
High-potency APIs (HPAPIs) account for 16.7% of the API segment and are among the highest-growth categories, underpinned by the rapid expansion of ADC programs in oncology; Lonza's dedicated HPAPI manufacturing suite in Visp, Switzerland and Cambrex's USD 120 million capacity expansion at its Charles City, Iowa facility adding 40% API output and specialized peptide manufacturing are representative of the infrastructure investment required to serve this sub-segment.
Finished Drug Formulations (FDF)
Finished drug formulations represent 59.1% of global pharmaceutical CDMO revenues in 2025, reflecting the scale of commercial-stage oral, injectable, and specialty dosage programs outsourced by both originator and generic drug companies. Solid-dose formulations account for 45.8% of FDF revenues, driven by the depth of oral small-molecule programs in commercial production including immediate-release, modified-release, and enteric-coated tablet and capsule formulations manufactured at high volume across US and European CDMO sites.
Liquid-dose formulations, encompassing sterile injectables and biologics drug products, contribute 28.6% of FDF segment revenues, a proportion that has expanded as parenteral biologics account for a growing share of FDA and EMA commercial approvals, with CDMOs investing in isolator-based vial filling lines and prefilled syringe capabilities to meet that demand. Semi-solid formulations represent 15.4% of FDF revenues, supported by dermatology, wound care, and topical anti-inflammatory programs, while other dosage forms including dry powder inhalers (DPIs), transdermal patches, ophthalmic solutions, and nasal delivery systems account for 10.2%, with inhaled biologics and combination drug-device products representing the most technically complex and fastest-growing sub-categories.
By Molecule Type
Small Molecule
The small molecule segment accounts for 62.1% of global pharmaceutical CDMO market revenues in 2025, reflecting the depth of the commercial pharmaceutical portfolio built on organic chemistry-based drug entities including branded and generic oral solids, controlled substances, highly potent compounds, and a growing category of synthetic peptides and oligonucleotides. Small-molecule API outsourcing reached 89% penetration among FDA novel drug approvals in 2025, the highest rate since tracking began and substantially above the 11-year average of 77%. This breadth of outsourcing adoption ensures that the small-molecule segment remains the market's revenue anchor regardless of pipeline innovation direction.
CDMOs serving this segment range from large-scale API synthesizers to specialist HPAPI manufacturers and peptide-focused operators: SK pharmteco's USD 260 million investment in a dedicated peptide and small-molecule manufacturing facility in Sejong, South Korea scheduled for late 2026 operations and Cambrex's Charles City expansion adding nearly one million liters of total API manufacturing capacity are representative of the capital commitments directed at this segment. Controlled substance manufacturing, which requires DEA-licensed facilities with specialized containment, is a structurally protected sub-segment where regulatory barriers limit competition and support margin resilience for qualified operators.
Large Molecule
The large molecule segment represents 37.9% of global pharmaceutical CDMO revenues in 2025, encompassing biologics drug substance and drug product manufacturing across monoclonal antibodies, fusion proteins, biosimilars, ADCs, cell therapies, gene therapies, mRNA-based medicines, and viral vector-based treatments. The segment's revenue share is growing structurally as biologics account for 45% of FDA novel drug approvals, biosimilar market entries accelerate global biologic manufacturing demand, and advanced therapy modalities transition from early clinical to commercial-scale production at CDMOs. Industry data indicates that 82.6% of cell and gene therapy facilities are now outsourcing at least some manufacturing activity the highest rate across all bioprocess platforms.
Large-molecule CDMO revenues carry significantly higher per-batch pricing than small-molecule equivalents, reflecting the complexity of upstream bioprocessing, downstream purification, and drug product fill-finish required for biologics. Samsung Biologics' cumulative bioreactor capacity exceeding 600,000 liters in Songdo, WuXi Biologics' global multi-site network holding 97 license approvals from regulatory agencies worldwide, and Fujifilm Diosynth Biotechnologies' 12 × 20,000-liter Hillerød site expansion collectively represent the scale and investment trajectory defining competitive positioning in the large-molecule manufacturing segment.
By Therapeutic Area
Oncology
Oncology represents the largest therapeutic area in the pharmaceutical CDMO market at 27.6% of global revenues in 2025, reflecting the outsized depth and complexity of the oncology drug pipeline encompassing cytotoxic small molecules, targeted biologics, monoclonal antibodies, bispecific antibodies, ADCs, CAR-T therapies, and radiopharmaceuticals. The oncology pipeline is the most diverse of any therapeutic area in terms of modality, requiring CDMOs to maintain competency across organic chemistry, mammalian cell culture, bioconjugation, viral vector production, and cell processing to serve a single customer's multi-program portfolio. ADCs are driving particularly significant CDMO infrastructure investment: Abzena's end-to-end ADC bioconjugation and sterile fill-finish platform and Piramal Pharma Solutions' USD 90 million Lexington, Kentucky expansion targeting ADC therapy manufacturing with batch output projected to more than double by late 2027 are representative of the specialized capital commitments directed at this sub-segment.
The FDA approved multiple oncology-focused novel drugs in 2025, including treatments for acute myeloid leukemia, breast cancer, ovarian cancer, multiple myeloma, and non-small cell lung cancer, each generating commercial manufacturing demand. Oncology's structural dominance of the pharmaceutical CDMO market is expected to persist through the forecast period as the late-stage pipeline remains among the deepest and most commercially consequential of any therapeutic category.
Infectious Diseases and Vaccines
Infectious diseases and vaccines represent 22.1% of global pharmaceutical CDMO revenues in 2025, the second-largest therapeutic area, driven by sustained manufacturing demand across antiviral drugs, antibiotics, and vaccine drug substances and drug products. The segment encompasses both commercial supply of approved infectious disease treatments and manufacturing capacity maintained for rapid response to emerging pathogens infrastructure significantly expanded during the COVID-19 pandemic that has partially transitioned to endemic infectious disease and respiratory programs.
Vaccine manufacturing represents a specialized CDMO sub-segment requiring adjuvant handling, lyophilization expertise, and high-volume fill-finish capability; Fujifilm Diosynth Biotechnologies and CordenPharma maintain dedicated vaccine manufacturing infrastructure serving both commercial programs and government-contracted preparedness supply. The EMA recommended approval of a medicine for respiratory syncytial virus (RSV) prevention in 2025, and active pipeline programs in influenza, dengue, and HIV-related conditions are sustaining manufacturing demand within the category. The broader policy-driven push toward pandemic preparedness manufacturing reserves supported by regulatory frameworks in the US and EU is sustaining investment in surge-capable manufacturing infrastructure at large CDMO sites, providing baseline revenue beyond commercial program volumes.
Metabolic and Endocrine
Metabolic and endocrine disorders account for 16.4% of global pharmaceutical CDMO market revenues in 2025, a therapeutic area experiencing accelerating demand driven primarily by the extraordinary commercial scale of GLP-1 receptor agonist programs including diabetes and obesity treatments requiring large-volume peptide API synthesis and injectable drug product manufacturing at a scale few CDMOs are currently equipped to meet in full. GLP-1-related programs have created a significant manufacturing bottleneck at CDMOs specializing in peptide APIs and injectable fill-finish, with several operators reporting capacity-constrained demand across 2024 and 2025.
Insulin analogues and biosimilar insulin programs represent additional substantial volume within this therapeutic area, requiring sterile liquid fill-finish and cold-chain logistics capabilities at commercial scale. CDMOs with large-scale peptide synthesis platforms including SK pharmteco with its forthcoming Sejong, South Korea facility and CordenPharma with dedicated peptide manufacturing operations are strategically positioned to capture incremental GLP-1 outsourcing volume as innovators and second-wave entrants ramp commercial supply globally. The metabolic and endocrine segment's CDMO revenue contribution is expected to grow faster than the market average through the late 2020s as expanding GLP-1 indications and geographic market launches amplify manufacturing demand.
Cardiovascular
The cardiovascular therapeutic area accounts for 14.3% of global pharmaceutical CDMO revenues in 2025, reflecting a large installed base of commercial small-molecule cardiovascular drugs statins, antihypertensives, anticoagulants, and antiarrhythmics alongside an emerging pipeline of biologics, oligonucleotides, and gene therapies targeting unmet needs in heart failure, lipid disorders, and rare cardiovascular conditions. Commercial manufacturing in the cardiovascular segment is predominantly small-molecule oral solid-dose, well-served by the broad base of FDA and EMA-compliant chemical API and finished formulation CDMOs.
The emerging cardiovascular biologics pipeline including PCSK9 inhibitors, antisense oligonucleotides targeting lipoprotein(a), and investigational cardiac gene therapies is introducing large-molecule and HPAPI manufacturing demand into the segment, diversifying service requirements beyond commodity solid-dose production. The FDA approved several novel cardiovascular drugs in 2025, including treatments for obstructive hypertrophic cardiomyopathy, hypercholesterolemia, and Barth syndrome, each requiring dedicated commercial manufacturing supply arrangements. The structural mix shift toward biologics and oligonucleotide-based cardiovascular therapies is expected to increase per-patient manufacturing complexity and CDMO revenue per program over the forecast period.
CNS and Psychiatry
Central nervous system (CNS) and psychiatry disorders represent 10.1% of global pharmaceutical CDMO revenues in 2025, encompassing a diverse pipeline of small molecules, peptides, and emerging biologics targeting depression, schizophrenia, Alzheimer's disease, Parkinson's disease, and rare neurological conditions. CNS drug development carries among the highest clinical attrition rates of any therapeutic area, which has historically constrained commercial manufacturing volumes relative to development-stage activity; however, approval rates for CNS novel drugs have improved in recent years as biomarker-guided development and adaptive trial designs have increased regulatory success rates.
The FDA approved several CNS-relevant drugs in 2025, including dordaviprone for diffuse midline glioma and treatments for hereditary angioedema, neurofibromatosis type 1, and Barth syndrome, sustaining commercial manufacturing demand within the category. Controlled substance manufacturing is a significant sub-segment within CNS, requiring DEA-licensed manufacturing facilities with specialized containment and inventory management infrastructure a regulatory barrier that concentrates competition and supports margin resilience for operators holding the necessary licenses. Cambrex's Charles City facility maintains controlled substance manufacturing authorization alongside HPAPI capability, exemplifying the integrated regulatory profile that complex CNS program outsourcing requires.
Other Therapeutic Areas
Other therapeutic areas collectively account for 9.5% of global pharmaceutical CDMO revenues in 2025, encompassing immunology, respiratory, gastrointestinal, rare diseases, dermatology, ophthalmology, and women's health. Rare disease programs including treatments approved under FDA Orphan Drug designation and EMA exceptional circumstances authorization represent a disproportionately high-value sub-segment within this category, as orphan drug manufacturing programs typically involve specialized formulations, small batch sizes, and precision analytical controls that command premium pricing per unit manufactured.
The EMA recommended 16 medicines for rare diseases in 2025 alone, including a first gene therapy to treat wounds in patients with dystrophic epidermolysis bullosa, reflecting a pipeline that will generate sustained CDMO demand in advanced therapy manufacturing. Immunology and respiratory programs including biologics for severe asthma, atopic dermatitis, and inflammatory bowel disease contribute substantial commercial manufacturing volume within this category. CDMOs serving these sub-segments, including Almac Group in rare disease solid-dose and specialty packaging and Recipharm in inhaled and injectable formulations, maintain differentiated service platforms relative to high-volume commodity manufacturing operators.
By End Use
Pharmaceutical Companies
Pharmaceutical companies represent the largest end-use category at 56.5% of global pharmaceutical CDMO market revenues in 2025, encompassing large-cap innovators, mid-sized specialty pharma companies, and established generic drug manufacturers that outsource API synthesis, finished drug product manufacturing, and ancillary services to specialized CDMOs. Large pharmaceutical companies increasingly use CDMOs not merely to flex manufacturing capacity around demand peaks, but as long-term strategic partners embedded across their commercial supply networks for both primary and backup supply. PhRMA member companies invested USD 104.3 billion in R&D in 2024,[5]PhRMA, phrma.org generating a volume of late-stage programs that requires CDMO commercial manufacturing capacity well in excess of what any individual company's internal facilities can accommodate.
Generic manufacturers are a distinct and substantial buyer segment within this category, outsourcing high-volume API synthesis and solid-dose manufacturing across Asian and European CDMO networks where cost competitiveness and scale are primary selection criteria. The strategic driver of this segment is the systematic unbundling of pharmaceutical manufacturing from core drug development and commercial functions, with large pharma companies retaining ownership of intellectual property, development strategy, and marketing while externalizing an increasing share of manufacturing execution.
Biotechnology Companies
Biotechnology companies account for 35.9% of global pharmaceutical CDMO revenues in 2025, representing the segment's most dynamic growth contributor as biotech's share of the global drug pipeline and commercial approval base continues to expand. Small and mid-sized biotech firms which represent the majority of molecules in late-stage clinical development globally are structurally dependent on CDMO partners for both development-stage process work and commercial manufacturing, given the capital investment required to build and operate GMP-compliant biologics and small-molecule manufacturing facilities.
Biopharma venture and public funding reached a 10-year high of USD 102 billion in 2024, sustaining biotech company formation rates and the pipeline of early-stage CDMO development engagements. CDMOs serving biotech clients must balance responsiveness and flexibility critical for early-stage companies managing uncertain clinical timelines and limited resources with the regulatory rigor and quality systems required by commercial-stage programs. The growth in this end-use segment is structurally linked to biologics pipeline expansion: as biologic biotech programs advance to commercialization, development agreements typically transition to long-term commercial supply contracts, increasing per-program revenue contribution without a change in client category.
Other End Users
Other end users represent 7.6% of global pharmaceutical CDMO revenues in 2025 and encompass virtual pharma companies, academic research institutions, government organizations, contract research organizations (CROs), animal health companies, and specialty pharma players. Virtual pharma companies asset-light drug developers that retain no in-house manufacturing capability and rely entirely on CDMO partners from discovery through commercialization are among the fastest-growing within this category, and their model is structurally aligned with the trend toward integrated CDMO partnerships. Academic and government organizations generate demand primarily for early-stage process development, clinical trial manufacturing, and, in the case of government health agencies, pandemic preparedness stockpile production under pre-negotiated frameworks.
Animal health represents a specialized sub-segment requiring GMP-compliant small-molecule and biologic manufacturing under regulatory frameworks analogous to human pharmaceutical requirements, with CDMOs including Recipharm and Siegfried serving select veterinary pharmaceutical clients. Specialty pharma players focused on orphan diseases, controlled substances, and niche formulations generate CDMO demand characterized by small batch sizes, specialized containment requirements, and extended client relationships given the complexity of regulatory qualification for specialty manufacturing processes.
By Region
North America Pharmaceutical CDMO Market
North America remains the largest pharmaceutical CDMO industry globally, accounting for 39.1% of revenues in 2025, underpinned by the world's highest concentration of pharmaceutical and biotech innovators, a robust FDA approval throughput of 46 novel drugs in 2025, and a well-capitalized CDMO infrastructure concentrated in New Jersey, North Carolina, Massachusetts, and California. The US has accelerated domestic manufacturing investment: Cambrex announced a USD 120 million expansion at its Charles City, Iowa facility in October 2025, adding 40% capacity for large-scale API and peptide production, while Piramal Pharma Solutions broke ground on a USD 90 million US facilities expansion in June 2025, targeting sterile injectables and ADC therapies at its Lexington, Kentucky site, with capacity projected to more than double to over 240 batches annually by late 2027.
Canada is an active secondary market, with capacity in sterile biologics and small-molecule APIs supporting both domestic supply and US export chains. In our Q3 2025 research with 18 CDMO operations leads across the US, 72% expected more than a quarter of their incremental commercial manufacturing business over 2026–2028 to originate from reshoring contracts previously held by Chinese CDMOs a development that is driving near-term capital deployment but constrained by the approximately 32-month average timeline to stand up new GMP-compliant facilities.
Europe Pharmaceutical CDMO Market
Europe accounts for 28.7% of global CDMO revenues in 2025, with Germany, Switzerland, France, the United Kingdom, and Ireland representing the region's primary manufacturing hubs. Switzerland, anchored by Lonza's Visp site and Siegfried's Zofingen facility, continues to concentrate HPAPI and biologics API manufacturing for global supply programs. Ireland has emerged as a significant biologics drug product destination: WuXi Biologics' Dundalk facility received its first EMA approval for commercial manufacturing of an innovative biologic in August 2025, building on 22 combined EMA and FDA approvals across its global facility network.
The EMA's record approval of 41 biosimilars in 2025 is generating incremental commercial manufacturing demand across European sites, as biosimilar market authorization requires EMA-approved manufacturing locations, directly benefiting CDMOs with established European regulatory track records. The UK maintains capacity in sterile fill-finish and clinical biologics manufacturing, with SEKISUI Diagnostics completing a £15.7 million cGMP capacity expansion at its UK microbial fermentation site in November 2024 enabling drug substance manufacturing for enzymes, proteins, antibody fragments, and gene therapy plasmids at up to 1,000-liter scale. Post-Brexit UK regulatory divergence from EU requirements continues to introduce incremental compliance overhead for CDMOs supplying both markets.
Asia Pacific Pharmaceutical CDMO Market
Asia Pacific accounts for 25.6% of global CDMO revenues in 2025 and is the fastest-growing region, with divergent but complementary strategic postures across China, India, Japan, and South Korea. Chinese CDMOs maintain dominant scale in small-molecule API synthesis and biologics drug substance manufacturing: WuXi Biologics commenced construction of a commercial microbial manufacturing site in Chengdu in May 2025, spanning 95,000 square meters with a 15,000-liter fermenter, projected annual output of 80 to 110 drug substance batches, and expansion potential to 60,000 liters alongside China's first dual-chamber lyophilization production line and drug product capacity exceeding 10 million vials annually.
Indian CDMOs are capturing incremental market share as global sponsors diversify supply chains; industry estimates indicate the China+1 shift could generate USD 700 million in incremental annual revenue for Indian CDMOs in the base case, with Syngene International and Piramal Pharma Solutions among the firms actively expanding capability. South Korean CDMOs are scaling rapidly, with Samsung Biologics targeting 20–25% annual revenue growth in 2025 and SK pharmteco announcing a USD 260 million investment in September 2024 to build a new 135,800-square-foot small-molecule and peptide manufacturing facility in Sejong, South Korea, scheduled for late-2026 operations.
Pharmaceutical CDMO Market Share
The pharmaceutical CDMO industry maintains a moderately fragmented competitive structure. Lonza Group AG holds the leading individual position at approximately 12% of global revenues, built on an integrated platform spanning small molecules, biologics, and advanced therapy manufacturing with commercial-scale biologics production centered on its Visp, Switzerland and Portsmouth, New Hampshire sites. Lonza's sustained regulatory track record including multiple FDA and EMA-approved commercial manufacturing sites and a leading 16% share of biologics API production among FDA-approved drugs since 2015 continues to differentiate its positioning in large-molecule programs. The top five players Lonza, Thermo Fisher Scientific, Catalent Inc., Samsung Biologics Co., Ltd., and WuXi Biologics Co., Ltd. collectively hold approximately 30% of the global market, leaving the remaining 70% distributed across a broad base of regional and specialized operators.
Thermo Fisher Scientific's Patheon division holds a 22% share of small-molecule finished-dose approvals and a 13% share of biologics finished-dose approvals among FDA-approved drugs analyzed since 2015, making it one of the most active commercial-scale drug product CDMOs globally. Catalent's finished-dose approval share reached 20% in 2025, above its long-run average of 17%, reflecting commercial ramp-up of biologics drug product programs that entered clinical manufacturing during the 2022–2024 period. Samsung Biologics is executing one of the sector's most aggressive capacity-led growth strategies, with transition to a pure-play CDMO model supporting a 20–25% annual revenue growth outlook for 2025.
The competitive landscape is bifurcating around technical capability. CDMOs with validated capacity in cell and gene therapy, ADCs, lipid nanoparticle (LNP) formulation, and HPAPI synthesis compete in a higher-value tier where selection is driven by technical track record and regulatory history rather than pricing alone. At the commodity tier covering standard oral solid-dose and non-sterile liquid manufacturing competition centers on cost, capacity availability, and proximity to major demand markets. M&A activity has remained a structural feature of the competitive landscape, with large strategic platforms selectively acquiring specialized CDMOs to close capability gaps in advanced modalities.
Conversations with 12 biopharma business development directors in our Q4 2025 expert panel consistently identified regulatory quality systems, prior experience with specific molecule types, and speed-to-commercial timeline as the top three CDMO selection criteria consistently ranking above pricing in initial evaluation. The data indicates that market concentration at the top has increased incrementally since 2020, though no single player has achieved dominance sufficient to materially alter the overall competitive dynamic, and mid-tier CDMOs continue to compete effectively on specialization and regulatory depth.
Pharmaceutical CDMO Market Companies
Major players operating in the pharmaceutical CDMO industry are:
Lonza Group AG is the global market leader, offering an integrated CDMO platform across small molecules, biologics, cell and gene therapies, and capsule technologies. Its mammalian cell culture biologics manufacturing in Visp and Portsmouth, combined with dedicated HPAPI suites and a global clinical development network, positions Lonza across the highest-value service categories in the market. The company's multi-decade regulatory track record and broad therapeutic area coverage underpin its dominant share.
Thermo Fisher Scientific operates one of the broadest global CDMO footprints, with more than 25 sites covering drug substance and drug product manufacturing for small molecules and biologics. The Patheon division leads small-molecule finished-dose and biologics finished-dose outsourcing share among FDA-approved commercial products, and its PharmaServices division provides integrated drug development solutions from formulation through commercial supply.
Catalent provides integrated development and supply solutions across biologics, gene therapy, oral drug delivery, and consumer health. Its Bloomington, Indiana biologics drug product site is among the largest FDA-approved biologics fill-finish facilities in North America, and its OptiForm and OptiMelt technologies represent proprietary platforms in oral bioavailability enhancement.
Samsung Biologics operates one of the world's largest single-site biologics manufacturing complexes in Songdo, South Korea, with more than 600,000 liters of cumulative bioreactor capacity. The company is transitioning to a pure-play CDMO model following the partial divestiture of Samsung Bioepis and is targeting 20–25% annual revenue growth in 2025, reflecting a rapidly expanding commercial manufacturing portfolio.
WuXi Biologics Co., Ltd. operates a global multi-site biologics CDMO network with facilities in China, Ireland, Germany, Singapore, and the United States. As of end-2024, WuXi Biologics had passed 42 regulatory inspections including 22 by EMA and FDA with zero critical findings, and holds 97 license approvals across global regulatory agencies.
Boehringer Ingelheim holds a differentiated position in the pharmaceutical CDMO market through its high‑quality biologics manufacturing capabilities across mammalian and microbial expression systems, supported by large-scale production sites in Europe and the United States. Its focus on complex biologics, robust regulatory expertise, and long-standing partnerships with global pharmaceutical companies enable delivery across clinical and commercial stages, positioning the company as a premium biologics CDMO player in high-value therapeutic segments.
Recipharm provides integrated drug product development and commercial manufacturing services across injectable, inhaled, and oral solid-dose formulations, with a strong European footprint spanning Sweden, France, Germany, and Italy. The company serves both innovative and generic pharmaceutical markets.
Siegfried Holding specializes in pharmaceutical chemistry and drug product manufacturing, with particular strength in APIs and oral solid-dose formulations across European sites including Zofingen and Hameln. Siegfried has expanded its service integration to include finished drug product manufacturing alongside API capabilities.
CordenPharma International offers end-to-end development and manufacturing services for complex APIs, peptides, lipids, and carbohydrates, with facilities in Switzerland, Germany, France, Italy, and the United States. Its lipid and carbohydrate platforms have gained relevance as LNP-based drug delivery systems expand.
Piramal Pharma Solutions is an integrated CDMO providing drug discovery, development, and manufacturing services, with 15 global facilities across North America, Europe, and India. A USD 90 million US capacity expansion focused on sterile injectables and ADC therapies is underway, with the Lexington site projected to more than double its batch output by late 2027.
Cambrex is a leading small-molecule CDMO specializing in API development and manufacturing, with strong capability in HPAPI, controlled substances, and peptide synthesis. A USD 120 million investment announced in October 2025 is expanding API manufacturing and peptide production capacity by 40% at its Charles City, Iowa facility, reinforcing its position in the growing peptide therapeutics market.
Fujifilm Diosynth Biotechnologies is a biologics-focused CDMO with mammalian cell culture and microbial fermentation capabilities across Denmark, the UK, the US, and Japan. Its Hillerød, Denmark site is undergoing a multi-phase expansion to 12 × 20,000-liter bioreactors with integrated fill-finish capability, representing one of the largest ongoing biologics drug substance capacity investments in Europe.
PCI Pharma Services provides clinical and commercial drug product manufacturing, packaging, and supply chain services. The company committed over USD 365 million to US and EU facility investment in 2024, including a 545,000-square-foot advanced drug delivery and drug-device combination assembly expansion in Rockford, Illinois, targeting clinical-to-commercial supply of injectables, autoinjectors, and prefilled syringes.
Almac Group offers integrated pharmaceutical development and manufacturing services spanning API synthesis, drug product formulation, packaging, and distribution. Operating from UK and US facilities, Almac serves clinical and commercial-stage biopharma with a focus on oral solid-dose, sterile injectables, and potent compounds.
Abzena provides integrated biologics CDMO services including bioconjugation, ADC manufacturing, and biologics drug product manufacturing from facilities in the UK and US. The company's ADC linker-payload chemistry capabilities and sterile fill-finish infrastructure position it within the high-growth ADC manufacturing sub-segment.
Syngene International is one of India's leading integrated CDMOs, offering discovery, development, and manufacturing services across small molecules and biologics from its Bengaluru, India campus. Syngene is actively expanding its CDMO customer base as global pharma companies implement China+1 supply chain diversification strategies, with management citing a continuing increase in client inquiries from Western biopharma rebalancing their supply chain networks.
12% Market Share
Collective Market Share is 30%
Pharmaceutical CDMO Industry News
Market Concentration Score
The pharmaceutical CDMO market scores 4 out of 10 on the concentration scale moderately fragmented, with the top five players (Lonza, Thermo Fisher Scientific/Patheon, Catalent, Samsung Biologics, and WuXi Biologics) collectively holding approximately 30% of global revenues, while the remaining 70% is distributed across a broad base of regional specialists and mid-tier operators, limiting any single firm's ability to exert pricing or structural control over the market.
The pharmaceutical CDMO market research report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue (USD Million) from 2022 to 2035, for the following segments:
Click here to Buy Section of this Report
Market, By Service
Market, By Product
Market, By Molecule Type
Market, By Therapeutic Area
Market, By End Use
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →